Company Revenue Reports

The company grew in the high teens as prior investments in new products and distribution more than offset COVID headwinds.

The company grew in the low single digits as enabling technology sales and strength in emerging markets helped offset COVID declines.

The company's MACI product declined in the low single digits for 3Q21 but Vericel expects a record-setting fourth quarter.

The company grew in the high single digits in 3Q21, led by shoulder implant sales and recent acquisitions.

The company grew in the high single digits for 3Q21, driven by an expanding user base and advantageous reimbursement agreements.

The company grew more than +51% in 3Q21, driven by an expanding active surgeon base and increased utlization per surgeon.

The company grew nearly +27% in the third quarter of 2021, with nearly half of that growth attributable to recently acquired Bioness.

The company grew in the double digits for 3Q21, aided by strong international sales in European and South American markets.

The company grew nearly 36% in FY 2Q21 as its domestic Japanese and international markets rebounded from pandemic lows in the prior year.

The company's 3Q21 sales fell in the high single digits due to the dual headwinds of COVID and OUS trauma product supply.